Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (lDet) and insulin aspart (IAsp) from the PREFER treat-to-target study

被引：0
|
作者：
Liebl, A.
Compion, G.
Prager, R.
Binz, K.
Kaiser, M.
Gallwitz, B.
机构：
[1] Ctr Diabet & Metab, Bad Heilbrunn, Germany
[2] Novo Nordisk Ltd, Crawley, England
[3] Inst Metab Dis & Nutr, Med Abt Stoffwechselerkrankungen & Nephrol, Vienna, Austria
[4] Triemli City Hosp, Dept Endocrinol & Diabet, Zurich, Switzerland
[5] Novo Nordisk Pharma GmbH, Dept Diabet, Mainz, Germany
[6] Univ Tubingen, Med Klin 4, Tubingen, Germany
来源：
DIABETIC MEDICINE | 2007年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [21] Biphasic Insulin Aspart 30/70 (BIAsp 30) Is Well Tolerated Effective in Patients ≥75 Years Old in the IMPROVE™ Study
    Borzi, Vito
    Rosenberg, Kristine Horn
    Benroubi, Marian
    [J]. DIABETES, 2010, 59 : A554 - A555
  • [22] IMPROVE study: initiation of biphasic insulin BIAsp30 in type 2 diabetics
    Valensi, Paul
    [J]. METABOLISMES HORMONES DIABETES ET NUTRITION, 2008, 12 (06): : 222 - 223
  • [23] Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial
    Kaneko, Shizuka
    Chow, Francis
    Choi, Dong Seop
    Taneda, Shinji
    Hirao, Koichi
    Park, Yongsoo
    Andersen, Thomas Hasseriis
    Gall, Mari-Anne
    Christiansen, Jens Sandahl
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 107 (01) : 139 - 147
  • [24] Pharmacokinetic and pharmacodynamic differences between premixed suspensions of insulin aspart: biphasic insulin aspart 30, 50 and 70
    Heise, T
    Kapitza, C
    Jacobsen, LV
    Brondsted, L
    Heinemann, L
    [J]. DIABETOLOGIA, 2005, 48 : A301 - A301
  • [25] A Comparison of Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30, 50, 70 and Pure Insulin Aspart: A Randomized, Quadruple Crossover Study
    Thorisdottir, Rannveig Linda
    Parkner, Tina
    Chen, Jian-Wen
    Ejskjaer, Niels
    Christiansen, Jens Sandahl
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 104 (03) : 216 - 221
  • [26] The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target<7.0%
    Liebl, A.
    Prager, R.
    Kaiser, M.
    Binz, K.
    Gailwitz, B.
    [J]. DIABETOLOGIA, 2006, 49 : 610 - 611
  • [27] Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study
    Yang, Wenying
    Gao, Yan
    Liu, Guoliang
    Chen, Lulu
    Fu, Zuzhi
    Zou, Dajin
    Feng, Ping
    Zhao, Zhigang
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (01) : 101 - 107
  • [28] Biphasic insulin aspart 30 improves postprandial glycemic control
    Hermansen, K
    Vaaler, S
    Madsbad, S
    Dalgaard, M
    Begtrup, K
    Lindholm, A
    [J]. DIABETES, 2001, 50 : A95 - A95
  • [29] Insulin Degludec/Insulin Aspart (IDegAsp) Provides Superior FPG Control and Reduced Hypoglycaemia vs. Biphasic Insulin Aspart 30 (BIAsp 30) in Insulin-Naive Adults with Type 2 Diabetes in a Randomized Phase 3 Trial
    Franek, Edward
    Haluzik, Martin
    Canecki-Varzic, Silvija
    Sargin, Mehmet
    Macura, Stanislava
    Zacho, Jeppe
    Christiansen, Jens Sandahl
    [J]. DIABETES, 2014, 63 : A225 - A225
  • [30] A comparison of pharmocodynamics and pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 & Pure Insulin Aspart in type 1 diabetes
    Thorisdottir, Rannveig L.
    Parkner, Tina
    Chen, Jian-Wen
    Ejskjaer, Niels
    Christiansen, Jens S.
    [J]. DIABETES, 2007, 56 : A555 - A555
12345